clinical studylínchuáng yánjiū临床研究shows / indicatesxiǎnshì显示new drugxīn yào新药zorevunersen (epilepsy drug)Zuǒléifúnàsēn佐雷伏纳森to cause / makeshǐ使Dravet syndrome (severe epilepsy)Délāwéi Zōnghézhēng德拉韦综合征children with the diseasehuàn ér患儿epilepsy / seizuresdiānxián癫痫attacks / episodesfāzuò发作at mostzuì duō最多to reducejiǎnshǎo减少90 percentjiǔ chéng九成。
March 4, 2026 at 10:00 PM
New Words
News in English
Lifestyle & CultureClinical Trial Shows New Drug Zorevunersen Cuts Seizures by Up to 91 Percent in Children With Dravet Syndrome
Published in the New England Journal of Medicine, the study confirmed zorevunersen can reduce monthly seizure frequency in children with Dravet syndrome by up to 91 percent. The research team found the drug also improved cognitive function and quality of life over a three-year period, and has already launched a larger Phase 3 trial.
A clinical study published in the New England Journal of Medicine demonstrates that the novel drug zorevunersen can reduce epilepsy attacks in children with Dravet syndrome by as much as approximately 90 percent.
Dravet syndrome is a rare and severe hereditary epilepsy triggered by mutations in the SCN1A gene. Currently, there are no clinical treatments available to cure it completely.
This study enrolled a total of 81 children aged between 2 and 18 years with the disease. Participants experienced approximately 17 seizure episodes per month on average before receiving treatment.
The drug's mechanism of action involves increasing the production of protein from healthy copies of the SCN1A gene, thereby restoring nerve cell function.
The study also found that over a three-year trial period, the drug helped children with the disease improve their cognitive function and quality of life, with the majority experiencing relatively mild adverse reactions.
The positive preliminary results prompted the research team to launch a larger-scale phase 3 clinical trial, with patient enrollment expected to complete in the second quarter of 2026.
Analysts believe that if phase 3 data receives verification, zorevunersen may become the first disease-modifying therapy for Dravet syndrome patients, achieving milestone significance.
More in Lifestyle & Culture
CanadaJiānádà加拿大poetshīrén诗人Anne Carson (Canadian poet)Ānnī Kǎsēn安妮·卡森to win / to be honored withrónghuò荣获20262026 nián2026年NobelNuòbèiěr诺贝尔Prize in Literaturewénxué jiǎng文学奖。
Canadian Poet Anne Carson Wins 2026 Nobel Prize in Literature
threesān wèi三位scientistskēxué jiā科学家for / because ofyīn因pioneeringkāichuàng开创optogeneticsguāng yíchuán xué光遗传学technologyjìshù技术jointlygòngtóng共同to be awardedrónghuò荣获20262026 nián2026年NobelNuòbèiěr诺贝尔Physiologyshēnglǐ xué生理学orhuò或Medicine Prizeyīxué jiǎng医学奖。
Three Scientists Win 2026 Nobel Prize in Medicine for Pioneering Optogenetics Technology
Molchanov (champion freediver)Mò ěr chá nuò fū莫尔查诺夫with / at (a score of)yǐ以137 meters137 mǐ137米to set / to establishchuàng创constant weighthéngzhòng恒重freedivingzìyóu qiánshuǐ自由潜水mennánzǐ男子world recordshìjiè jìlù世界纪录。
Alexey Molchanov Sets Freediving World Record With 137-Meter Dive at World Championships in Limassol
CanadaJiā ná dà加拿大author / writerzuò jiā作家Anne Carson (Canadian author)Ān nī Kǎ sēn安妮·卡森to be honored with / to winróng huò荣获the year 20262026 nián2026年NobelNuò bèi ěr诺贝尔Prize in Literaturewén xué jiǎng文学奖。
Canadian Author Anne Carson Wins 2026 Nobel Prize in Literature